share_log

CVS Health | 8-K: Current report

CVS Health | 8-K: Current report

西維斯健康 | 8-K:重大事件
美股sec公告 ·  05/09 04:45
牛牛AI助理已提取核心訊息
On May 7, 2024, CVS Health Corporation entered into an Underwriting Agreement with a consortium of underwriters led by BofA Securities, Inc., Barclays Capital Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, and Wells Fargo Securities, LLC. The agreement outlines the sale of $5 billion in Senior Notes with varying maturity dates ranging from 2029 to 2054 and interest rates from 5.400% to 6.050%. The sale is set to close on May 9, 2024, contingent on customary closing conditions. The net proceeds from the sale, after underwriting discounts and estimated offering expenses, are expected to be approximately $4.95 billion. The offering is made under the Company's Registration Statement on Form S-3ASR, dated May 25, 2023. The Underwriting Agreement has been filed with the SEC and is incorporated into the Registration Statement.
On May 7, 2024, CVS Health Corporation entered into an Underwriting Agreement with a consortium of underwriters led by BofA Securities, Inc., Barclays Capital Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, and Wells Fargo Securities, LLC. The agreement outlines the sale of $5 billion in Senior Notes with varying maturity dates ranging from 2029 to 2054 and interest rates from 5.400% to 6.050%. The sale is set to close on May 9, 2024, contingent on customary closing conditions. The net proceeds from the sale, after underwriting discounts and estimated offering expenses, are expected to be approximately $4.95 billion. The offering is made under the Company's Registration Statement on Form S-3ASR, dated May 25, 2023. The Underwriting Agreement has been filed with the SEC and is incorporated into the Registration Statement.
2024年5月7日,CVS Health Corporation與由美銀證券公司、巴克萊資本公司、高盛公司牽頭的承銷商財團簽訂了承保協議。有限責任公司、摩根大通證券有限責任公司和富國銀行證券有限責任公司。該協議概述了出售50億美元的優先票據,其到期日從2029年到2054年不等,利率從5.400%到6.050%不等。此次拍賣定於2024年5月9日結束,視慣例成交條件而定。扣除承保折扣和預計發行費用後,此次出售的淨收益預計約爲49.5億美元。此次發行是根據公司於 2023 年 5 月 25 日在 S-3ASR 表格上發佈的註冊聲明進行的。承保協議已向美國證券交易委員會提交併已納入註冊聲明。
2024年5月7日,CVS Health Corporation與由美銀證券公司、巴克萊資本公司、高盛公司牽頭的承銷商財團簽訂了承保協議。有限責任公司、摩根大通證券有限責任公司和富國銀行證券有限責任公司。該協議概述了出售50億美元的優先票據,其到期日從2029年到2054年不等,利率從5.400%到6.050%不等。此次拍賣定於2024年5月9日結束,視慣例成交條件而定。扣除承保折扣和預計發行費用後,此次出售的淨收益預計約爲49.5億美元。此次發行是根據公司於 2023 年 5 月 25 日在 S-3ASR 表格上發佈的註冊聲明進行的。承保協議已向美國證券交易委員會提交併已納入註冊聲明。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。